W Kruis

Charité Universitätsmedizin Berlin, Berlín, Berlin, Germany

Are you W Kruis?

Claim your profile

Publications (287)1106.02 Total impact

  • Zeitschrift für Gastroenterologie 08/2015; 41(08). DOI:10.1055/s-0035-1555247 · 1.05 Impact Factor
  • Roland H Pfützer · Wolfgang Kruis
    [Show abstract] [Hide abstract]
    ABSTRACT: Diverticular disease is a common condition in Western countries and the incidence and prevalence of the disease is increasing. The pathogenetic factors involved include structural changes in the gut that increase with age, a diet low in fibre and rich in meat, changes in intestinal motility, the concept of enteric neuropathy and an underlying genetic background. Current treatment strategies are hampered by insufficient options to stratify patients according to individual risk. One of the main reasons is the lack of an all-encompassing classification system of diverticular disease. In response, the German Society for Gastroenterology and Digestive Diseases (DGVS) has proposed a classification system as part of its new guideline for the diagnosis and management of diverticular disease. The classification system includes five main types of disease: asymptomatic diverticulosis, acute uncomplicated and complicated diverticulitis, as well as chronic diverticular disease and diverticular bleeding. Here, we review prevention and treatment strategies stratified by these five main types of disease, from prevention of the first attack of diverticulitis to the management of chronic complications and diverticular bleeding.
    Nature Reviews Gastroenterology &#38 Hepatology 07/2015; DOI:10.1038/nrgastro.2015.115 · 12.61 Impact Factor
  • Wolfgang Kruis · Phuong Nguyen · Julia Morgenstern
    [Show abstract] [Hide abstract]
    ABSTRACT: Adsorptive granulocyte/monocyte apheresis (GMA) has shown promising efficacy in the treatment of patients with ulcerative colitis (UC). But a sham-controlled study was negative. A post-hoc analysis of this trial may haul out patients responding to GMA. A total of 168 UC patients with a disease activity (DAI) between 6 and 11 were enrolled in this study. Out of 168 patients, 112 received GMA and 56 sham apheresis. The basis for this post hoc analysis is the clinical study report issued by Otsuka America Pharmaceutical. Baseline histology was available for 165 patients. Only 38% (63 of 165) of patients showed microscopic erosion/ulceration (group P). The remaining 62% of patients did not show microscopic erosion/ulceration (group A). The patients in group P showed significantly higher DAI, flexible proctosigmoidoscopy score and neutrophil infiltration into the colonic mucosa than those in group A (p = 0.0132, p = 0.0243 and p < 0.0001, respectively). Likewise, group P patients had a significantly (p = 0.0275) higher remission rate (11 of 46; 23.9%) when treated with GMA than with sham procedure (0 of 17; 0%). Patients in group P who had more active UC than those in group A showed clear clinical efficacy in response to GMA. We believe that true DAI should be specified for further randomized controlled trials. © 2015 S. Karger AG, Basel.
    Digestion 06/2015; 92(1):39-44. DOI:10.1159/000431149 · 2.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vedolizumab, the first drug in the class of anti-integrin molecules, is newly approved for ulcerative colitis and Crohn's disease and can be prescribed in Germany since mid-2014. By a specific receptor binding a relatively gut-selective mode of action was achieved without the known side effects of the systemic immunosuppression of the anti-TNF-alpha antibodies. According to the present data the safety profile of Vedolizumab appears to be more favorable than that of the anti-TNF- alpha therapy. Vedolizumab is suitable for induction therapy in patients with ulcerative colitis and Crohn's disease, however the kinetic of response compared with the anti-TNF-alpha antibodies seems to be slower. For maintenance therapy the Vedolizumab data show a deep and sustained remission in patients initially responding to induction therapy with a lower loss of efficacy in the long-term treatment known from the anti-TNF-alpha therapy. On the basis of currently available data the efficacy of Vedolizumab in ulcerative colitis appears to be slightly better than in Crohn's disease. © Georg Thieme Verlag KG Stuttgart · New York.
    Zeitschrift für Gastroenterologie 05/2015; 53(6). DOI:10.1055/s-0034-1399400 · 1.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Early detection of neoplastic lesions is essential in patients with long-standing ulcerative colitis but the best technique of colonoscopy is still controversial. We performed a prospective multicenter study in patients with long-standing ulcerative colitis. Two colonoscopies were performed in each patient within 3 weeks to 3 months. In white-light (WL) colonoscopy stepwise random biopsies (4 biopsies every 10cm), segmental random biopsies (2 biopsies in 5 segments) and targeted biopsies were taken. In NBI colonoscopy segmental and targeted biopsies were taken. The sequence of WL and NBI colonoscopy was randomized. In 36 of 159 patients enrolled (22.6%) 54 lesions with intraepithelial neoplasia (IN) were found (51 low-grade, 3 high-grade). In WL colonoscopy we found 11 IN in stepwise, 4 in segmental and 15 in targeted biopsies. In NBI colonoscopy 7 IN were detected in segmental and 24 IN in targeted biopsies. Almost all IN were found in one technique alone (Kappa value of WL versus NBI: -0.86, p<0.001). Statistically equivalent numbers of IN were found in NBI colonoscopy with targeted and segmental biopsies as in WL colonoscopy with targeted and stepwise biopsies but fewer biopsies (11.9 versus 38.6 biopsies, p<0.001) and less withdrawal time was necessary (23 versus 13 minutes, p<0.001). Stepwise biopsies are indispensable in WL colonoscopy. The combination of targeted and segmental biopsies in NBI technique is as sensitive as targeted together with stepwise biopsies in WL colonoscopy but requires fewer biopsies and less time. Highest sensitivity should be reached by combining WL and NBI technique by switching between the modes. Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.
    Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 05/2015; DOI:10.1016/j.cgh.2015.04.172 · 7.90 Impact Factor
  • Gastroenterology 04/2015; 148(4):S-334-S-335. DOI:10.1016/S0016-5085(15)31110-0 · 16.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cerebro-vascular accidents (CVA) have rarely been reported in inflammatory bowel disease (IBD) patients treated with anti-tumor necrosis alpha (anti-TNFalpha) agents. Our aim here was to describe the clinical course of CVA in these patients. This was a European Crohn's and Colitis Organization (ECCO) retrospective observational study, performed as part of the CONFER project. A call to all ECCO members was made to report on IBD patients afflicted with CVA during treatment with anti-TNFalpha agents. Clinical data were recorded in a standardized CRF and analyzed for event association with anti-TNFalpha treatment. Nineteen patients were identified from 16 centers: Fourteen had Crohn's disease, four ulcerative colitis and one IBD colitis unclassified (median age at diagnosis: 38.0 years, range: 18.6-62.5). Patients received anti-TNFalpha for a median duration of 11.8 months (range: 0-62) at CVA onset and 7 had previously been treated with at least one other anti-TNFalpha agent. Complete neurological recovery was observed in 16 patients. Anti-TNFalpha was discontinued in 16/19 patients. However, recurrent CVA or neurologic deterioration was not observed in any of the 11 patients who received anti-TNFalpha after CVA (8 resumed after temporary cessation, 3 continued without interruption) for a median follow-up of 39.8 months (range: 5.6-98.2). These preliminary findings do not unequivocally indicate a causal role of anti-TNFalpha in CVA complicating IBD. Resuming or continuing anti-TNFalpha in IBD patients with CVA may be feasible and safe in selected cases, but careful weighing of IBD activity versus neurological status is prudent. Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
    Journal of Crohn s and Colitis 03/2015; 9(5). DOI:10.1093/ecco-jcc/jjv042 · 6.23 Impact Factor
  • Source
    Zeitschrift für Gastroenterologie 12/2014; 52(12):1431-84. DOI:10.1055/s-0034-1385199 · 1.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Diverticular disease is one of the most common disorders of the gastrointestinal tract. 28-45% of the population develop colonic diverticula, while about 25% suffer symptoms and about 5% complications. Aim: To create formal guidelines for diagnosis and management. Methods: Six working groups with 44 participants analyzed key questions in subject areas assigned to them. Following a systematic literature search, 451 publications were included. Consensus was obtained by agreement within the working groups, two Delphi processes and a guideline conference. Results: Targeted management of diverticular disease requires a classificatory diagnosis. A new classification was created. In addition to the clinical examination, intestinal ultrasound or computed tomography is the determining factor. Interval colonoscopy is recommended to exclude comorbidities. A low-fiber diet, obesity, lack of exercise, smoking and immunosuppression have an adverse impact on diverticulosis. This can lead to diverticulitis. Antibiotics are no longer recommended in uncomplicated diverticulitis if no risk factors such as immunosuppression are present. If close monitoring is ensured, uncomplicated diverticulitis can be treated on an outpatient basis. Complicated diverticulitis should be treated in hospital, involving broad-spectrum antibiotic therapy, where necessary abscess drainage, and surgery, if possible laparoscopically. In the case of chronic relapsing diverticulitis, the risk of perforation decreases with each episode, so that surgery is no longer recommended after the second episode but only following individual assessment. Conclusions: New findings on diverticular disease call into question the overuse of antibiotics and excessive indications for surgery. Targeted treatment requires a precise diagnosis and intensive interdisciplinary cooperation. © 2014 S. Karger AG, Basel.
    Digestion 11/2014; 90(3):190-207. DOI:10.1159/000367625 · 2.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Obesity is a risk factor for inflammatory diseases such as nonalcoholic steatohepatitis, pancreatitis, and Crohn's disease. The effect of being overweight or obese on the severity and clinical course of ulcerative colitis (UC) was assessed in a retrospective analysis of data from 2000-2006. Methods: Two hundred and two consecutive UC patients were categorized according to body mass index (BMI). Patient and disease characteristics were compared between BMI categories using chi-square or Kruskal-Wallis tests. The percentage of patients with active UC, complications, steroid therapy, or immunosuppressive therapy was calculated for each group, and matched pair analyses were performed. Results: Ten patients (5%) were underweight, 111 (55%) were normal weight, 54 (26.7%) were overweight, and 27 (13.4%) were obese. Pancolitis was inversely related to weight. BMI was also inversely correlated to disease severity, with a significantly smaller proportion of years with chronic active disease among overweight subjects versus normal-weight subjects (17.6 versus 23.9%, p = 0.05). More overweight than normal-weight patients had no chronic active disease in any year (66 versus 49%, p = 0.06), and the proportion of years with disease complications was higher in normal weight than in overweight subjects (1.8 versus 0.4%, p = 0.08). Disease activity during 2000-2006 was higher for underweight versus normal-weight patients, and only 20% of underweight subjects had no hospital admission compared to 80% of normal-weight patients (p = 0.07). Conclusions: This first study to explore the influence of obesity on UC showed that high BMI had rather a favorable effect on the prognosis, whereas low BMI pointed to a more severe course of the disease.
    International Journal of Colorectal Disease 11/2014; 30(2). DOI:10.1007/s00384-014-2051-3 · 2.45 Impact Factor
  • Source
    Stephan Karl Böhm · Wolfgang Kruis
    [Show abstract] [Hide abstract]
    ABSTRACT: In 1977, 5-aminosalicylic acid (5-ASA) was discovered as a therapeutically active moiety of sulfasalazine (SASP) and was launched for topical and oral therapy of ulcerative colitis (UC) in 1984. As a first-step, delivery systems had to be developed to protect 5-ASA against absorption in the upper gastrointestinal tract, resulting in different and competing strategies (azo compounds, controlled release, and pH-dependent release). In a second step, at the beginning of the new century, coinciding with the expiration of patent protection for the first 5-ASA formulations, two component composite release mechanisms (pH-dependent and controlled release) were developed. Furthermore, the drug was formulated as granules instead of tablets, allowing higher unit strengths compared with tablets. Neither Salofalk Granu-Stix®, nor MMX 5-ASA, nor Pentasa® granules have initially been developed for once-daily (OD) dosing. A review of the achievements of 20 years of 5-ASA development has demonstrated that 5-ASA has equal efficacy compared with SASP at best, that there are no measurable differences in efficacy between various 5-ASA preparations, and that in a group of patients tolerating SASP, adverse event profiles of SASP and 5-ASA did not differ significantly, with SASP being the far cheaper substance. Therefore, drug adherence came into focus as a new goal for improving UC therapy. Although adherence is a complex and multifactorial construct, a simple dosing schedule may contribute to higher drug adherence and better efficacy of treatment. Simultaneously, the US 5-ASA market, estimated to be worth US$1.4 billion, is expected to grow continuously. Naturally, this very competitive market is not only driven by scientific progress but also by commercial interests. Thus, patents for minor changes to the formulation may serve as protection against drug companies trying to launch generic versions. Randomized controlled trials performed on OD dosing in induction of remission have demonstrated that OD administration of 5-ASA is as effective as conventional dosing in mild to moderate active UC. The three 5-ASA products MMX, Salofalk®, and Pentasa® employed in those studies so far have not shown differences in efficacy between OD and conventional dosing. No differences regarding safety outcomes have been detected between OD and conventional dosing, including incidence of adverse events, serious adverse events, or withdrawal from treatment due to an adverse event. Although the majority of patients prefer OD dosing to conventional dosing, it was not possible to detect differences in adherence between OD and multiple dose regimens in the clinical trial setting. Well-designed and controlled large-scale community-based studies are necessary to further investigate and prove the point of improved long-term adherence and treatment efficacy in OD dosing.
    Clinical and Experimental Gastroenterology 09/2014; 2014: 7:369 - 383. DOI:10.2147/CEG.S35691
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim: To detect high risk patients with a progressive disease course of ulcerative colitis (UC) requiring immunosuppressive therapy (IT). Methods: A retrospective, multicenter analysis of 262 UC patients from eight German tertiary inflammatory bowel disease centres was performed. Patients were divided into two groups depending on the patients need to initiate immunosuppressive therapy in the disease course. A comparison between the two groups was made with regard to demographics, clinical and laboratory parameters obtained within three months after UC diagnosis and the response to first medical therapy. Using this data, a prognostic model was established to predict the individual patients probability of requiring an immunosuppressive therapy. Results: In 104 (39.7%) out of 262 patients, UC therapy required an immunosuppressive treatment. Patients in this group were significantly younger at time of diagnosis (HR = 0.981 ± 0.014 per year, P = 0.009), and required significantly more often a hospitalisation (HR = 2.5 ± 1.0, P < 0.001) and a systemic corticosteroid therapy at disease onset (HR = 2.4 ± 0.8, P < 0.001), respectively. Response to steroid treatment was significantly different between the two groups of patients (HR = 5.2 ± 3.9 to 50.8 ± 35.6 compared to no steroids, P = 0.016 to P < 0.001). Furthermore, in the IT group an extended disease (HR = 3.5 ± 2.4 to 6.1 ± 4.0 compared to proctitis, P = 0.007 to P = 0.001), anemia (HR = 2.2 ± 0.8, P < 0.001), thrombocytosis (HR = 1.9 ± 1.8, P = 0.009), elevated C-reactive protein (CRP) (HR = 2.1 ± 0.9, P < 0.001), and extraintestinal manifestations in the course of disease (HR = 2.6 ± 1.1, P = 0.004) were observed. Six simple clinical items were used to establish a prognostic model to predict the individual risk requiring an IT. This probability ranges from less than 2% up to 100% after 5 years. Using this, the necessity of an immunosuppressive therapy can be predicted in 60% of patients. Our model can determine the need for an immunosuppressive drug therapy or if a "watch and wait" approach is reasonable already early in the treatment course of UC. Conclusion: Using six simple clinical parameters, we can estimate the patients individual risk of developing a progressive disease course.
    World Journal of Gastroenterology 09/2014; 20(35):12574-80. DOI:10.3748/wjg.v20.i35.12574 · 2.37 Impact Factor
  • Zeitschrift für Gastroenterologie 08/2014; 52(08). DOI:10.1055/s-0034-1386297 · 1.05 Impact Factor
  • Zeitschrift für Gastroenterologie 08/2014; 52(08). DOI:10.1055/s-0034-1386041 · 1.05 Impact Factor
  • Source
    Zeitschrift für Gastroenterologie 07/2014; 52(7):663. DOI:10.1055/s-0034-1366692 · 1.05 Impact Factor
  • Gastroenterology 05/2014; 146(5):S-370. DOI:10.1016/S0016-5085(14)61337-8 · 16.72 Impact Factor
  • Source
    Gastroenterology 05/2014; 146(5):S-187. DOI:10.1016/S0016-5085(14)60663-6 · 16.72 Impact Factor
  • Journal of Crohn s and Colitis 02/2014; 8:S41. DOI:10.1016/S1873-9946(14)60080-5 · 6.23 Impact Factor
  • Journal of Crohn s and Colitis 02/2014; 8:S227-S228. DOI:10.1016/S1873-9946(14)60509-2 · 6.23 Impact Factor
  • Journal of Crohn s and Colitis 02/2014; 8(5):S36. DOI:10.1016/S1873-9946(14)60069-6 · 6.23 Impact Factor

Publication Stats

5k Citations
1,106.02 Total Impact Points

Top co-authors View all


  • 2015
    • Charité Universitätsmedizin Berlin
      Berlín, Berlin, Germany
  • 1993–2015
    • Evangelisches Krankenhaus Kalk
      Köln, North Rhine-Westphalia, Germany
  • 1989–2013
    • University of Cologne
      • • Department of Internal Medicine
      • • Institute of Medical Statistics, Epidemiology and Computer Science
      Köln, North Rhine-Westphalia, Germany
    • Institut für klinische Pharmakologie
      Stuttgart, Baden-Württemberg, Germany
  • 2012
    • Cork University Hospital
      Corcaigh, Munster, Ireland
  • 2011
    • Frankfurt Diakonia Clinics
      Frankfurt, Hesse, Germany
  • 2008
    • Evangelic Hospital Bielefeld
      Bielefeld, North Rhine-Westphalia, Germany
    • St. Marien- und St. Annastiftskrankenhaus
      Ludwigshafen, Rheinland-Pfalz, Germany
  • 2001–2006
    • Universität Heidelberg
      Heidelburg, Baden-Württemberg, Germany
  • 2005
    • University of Tuebingen
      • Department of Psychosomatic Medicine
      Tübingen, Baden-Wuerttemberg, Germany
    • Klinikum Ludwigshafen
      Ludwigshafen, Rheinland-Pfalz, Germany
    • Kreiskrankenhaus Gummersbach GmbH
      Gummersbach, North Rhine-Westphalia, Germany
  • 2001–2003
    • University Hospital Essen
      Essen, North Rhine-Westphalia, Germany
  • 2000
    • Universität des Saarlandes
      Saarbrücken, Saarland, Germany
  • 1999
    • Klinikum Karlsruhe
      Carlsruhe, Baden-Württemberg, Germany
  • 1993–1998
    • University of Bonn
      Bonn, North Rhine-Westphalia, Germany
  • 1997
    • Humboldt-Universität zu Berlin
      Berlín, Berlin, Germany
  • 1988–1992
    • Ludwig-Maximilians-University of Munich
      • Department of Internal Medicine II
      München, Bavaria, Germany